Klin Farmakol Farm. 2004;18(4):212-214

Farmakoterapie Alzheimerovy choroby

Roman Jirák
Psychiatrická klinika 1. LF UK a VFN Praha

Keywords: Alzheimer´s disease, dementia, pharmacotherapy, acetylcholinesterase inhibitors, cognitive drugs, memantine.

Published: December 31, 2004  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Jirák R. Farmakoterapie Alzheimerovy choroby. Klin Farmakol Farm. 2004;18(4):212-214.

V současné době ještě plně neznáme etiologii Alzheimerovy choroby. Proto v terapii vycházíme ze známých etiologických řetězců. Pro lehké až střední formy alzheimerovské demence jsou indikovány inhibitory acetylcholinesterázy, pro těžší stadia pak antagonista glutamátových receptorů NMDA memantin. Jsou rozebrány ještě další možnosti terapie, které však již nejsou jednoznačně založeny na důkazech.

PHARMACOTHERAPY OF ALZHEKIMER´S DISEASE

At present time, there is not well known the ethiology of Alzheimer´s disease. That is why we use the pharmacotherapy derived from known pathogenetic chains. For mild- to moderate Alzheimer dementia there are established the acetylcholinesterase inhibitors, for advanced forms of Alzheimer dementia it is memantine. In the article there are discussed also another forms of pharmacotherapy, but those forms of pharmacotherapy are not evidence-based unambiguously.

Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Aguglia E, Onor ML, et al. Comparison of rivastigmine, donepezil and galantamine in the real-world setting. Poster presented ad: 6th International Conference on Alzheimer´s and Parkinson´s; May 8-12, 2003; Seville, Spain.
    2. Cummings JL. Cholinesterase inhibitors: expanding indications. Lancet, 2000; 356: 2024-2025. Go to original source... Go to PubMed...
    3. Feldman H (Ed.). Cholinesterase inhibitor therapy for Alzheimer´s disease and related dementias. Internat. Psychogeriatrics, 2002; 14, Suppl. 1. Go to original source... Go to PubMed...
    4. Giacobini E. Cholinesterases and cholinesterase inhibitors. London, Martin Dunitz, 2000: 270.
    5. Jirák R. Farmakoterapie Alzheimerovy choroby. In: Růžička E. et al. Diferenciální diagnostika a léčba demencí. Galén, Praha, 2003.
    6. Jirák R, Koukolík F. Demence. Galén, Praha, 2004: 335 s.
    7. Owens CT. Estrogen replacement therapy for Alzheimer´s disease in postmenopausal women. Ann Pharmacother, 2002; 36: 970-973. Go to original source... Go to PubMed...
    8. Qizilbash N, Schneider LS, Chui H, Tariot P, Brodaty H, Kaye J, Erkinjuntti T, eds. Evidence-based dementia practice. Oxford: Blackwell Science Ltd a Blackwell publishing company, 2003: 428-446.
    9. Sano M, et al. A controlled trial of selegiline, alpha-tocopherol or both as treatment for Alzheimer´s disease. The Alzheimer´s disease cooperative study. N Engl J Med, 1997; 336: 1216-1222. Go to original source... Go to PubMed...
    10. Scott HD, Laake K. Statins for the prevention of Alzheimer´s disease (Cochrane review). The Cochrane library, Oxford 2003: 2.
    11. Švestka J. Galantamin - dualistické kognitivum. Psychiatrie, 2001; 4: 2065-2074.
    12. Williams PS, Rands G, Orrel M, et al. Aspirin for vascular dementia (Cochrane review). Oxford, 2003: 2.
    13. Zoller B, Hock C, Kull H. Rational therapy of Alzheimer´s dementia based on current clinical studies. Schweiz Rundsch Med Prax. 2001; 90, No. 19: 827-834.

    Return to the content


    Clinical Pharmacology and Pharmacy

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.